Summary: The results of AI-based classifiers for lung cancer using Qlucore Insights were presented at The Molecular Analysis for Precision Oncology Congress 2024, demonstrating high accuracy in analyzing lung tumors and diseases.

Takeaways:

An IVDR-compliant solution for the lung cancer model is in development, and Qlucore Insights also supports models for leukemia and bladder cancer. 

Qlucore Insights’ Lung model can reproduce histopathological classification of lung tumors with high accuracy.

The lung classifier model, developed in collaboration with Heidelberg University Hospital, is available for research use and integrated into the Qlucore Insights software.


The results on AI-based classifiers for lung cancer were generated using Qlucore Insights and presented at The Molecular Analysis for Precision Oncology Congress 2024, in London, UK. This study demonstrates that Qlucore Insights can analyze lung tumors and lung diseases with high accuracy. 

”We are excited to share this promising data from our Qlucore Insights Lung model and how it can reproduce histopathological classification of tumors.” says Carl-Johan Ivarsson, CEO.

Classifiers Provide Groundbreaking Solution for Lung Cancer Diagnostics

Together with Heidelberg University Hospital, Qlucore previously secured funding from the Eurostars program in 2021. The aim of this partnership is to develop a ground-breaking solution for cancer classification and diagnostics based on RNA-sequencing data, including AI powered machine learning based classifiers.

The collaboration has resulted in the lung classifier model, which was presented as a poster by Alejandro Pallares Robles et al. The results show that Qlucore Insights can effectively analyze lung tumors, helping to classify them.

The lung cancer model is available for use (research use only) and is integrated into the Qlucore Insights software. An IVDR-compliant solution is currently under development. The lung cancer model is one of several models supported by the Qlucore Insights platform which also includes leukemia and bladder cancer.

Featured Image: Qlucore CEO Carl-Johan Ivarsson. Photo: Qlucore